The 21st Chinese Pharmaceutical Association Science and Technology Award was presented at the 2026 Chinese Pharmaceutical Congress. The project "New Drug Creation and Industrial Innovation for Antidepressants Combining Traditional Chinese Medicine Syndromes," in which Kanghong Pharmaceutical played a significant role, won the first prize.
The Chinese Pharmaceutical Association Science and Technology Award was officially approved by the Ministry of Science and Technology in July 2005. It is sponsored by the Chinese Pharmaceutical Association and recognizes researchers and innovative achievements that have made major breakthroughs in pharmaceutical science. It is a highly prestigious and influential award in the domestic pharmaceutical field.
Kanghong Pharmaceutical's Shugan Jieyu Capsules are the core landmark achievement of this award-winning project. As the first approved traditional Chinese medicine for mild to moderate depression in China, this product is a Class II protected TCM variety and was recently included in the National Essential Medicines List (2026 Edition). Since its launch, studies on Shugan Jieyu Capsules have achieved major breakthroughs in the construction of a syndrome-disease combination evaluation system, analysis of antidepressant active substances, and elucidation of pharmacological mechanisms.
This award fully demonstrates the groundbreaking significance of Shugan Jieyu Capsules in clinical application and industrialization, and signifies the industry's high recognition of Kanghong Pharmaceutical's achievements in innovative TCM R&D.

Source: https://news.yaozh.com/archive/49024.html